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a b s t r a c t
We previously found that human pegivirus (HPgV; formerly GBV-C) NS3 protease activity inhibits
Human Immunodeﬁciency Virus (HIV) replication in a CD4þ T cell line. Given the protease's similarity to
the Hepatitis C virus (HCV) NS3 protease, we characterized HPgV protease activity and asked whether it
affects the type I interferon response or is inhibited by HCV protease antagonists. We characterized the
activity of proteases with mutations in the catalytic triad and demonstrated that the HCV protease
inhibitors Telaprevir, Boceprevir, and Danoprevir do not affect HPgV protease activity. HPgV NS3
protease cleaved MAVS but not TRIF, and it inhibited interferon responses sufﬁciently to enhance
growth of an interferon-sensitive virus. Therefore, HPgV's inhibition of the interferon response could
help promote HPgV persistence, which is associated with clinical beneﬁts in HIV-infected patients. Our
results also imply that HCV protease inhibitors should not interfere with the beneﬁcial effects of HPgV in
HPgV/HCV/HIV infected patients.
Published by Elsevier Inc.
Introduction
The human variant of Pegivirus A, [HPgV; formerly GB Virus-C
(GBV-C)], is a non-vector borne pan-lymphotropic pegivirus
(George et al., 2006; Stapleton et al., 2011) which is spread by
blood and body ﬂuids, including sexual contact (Bjorkman et al.,
2001; Lefrere et al., 1999; Scallan et al., 1998; Supapol et al., 2008).
Approximately 2% of healthy blood donors have viral RNA in
serum and 8% have antibodies against the HPgV E2 protein
indicating prior infection (Alter et al., 1997). No clinical disease
has been conclusively associated with HPgV infection in humans
(Alter, 1997; Guidicelli et al., 2012; Jones et al., 2005; Krajden et al.,
2010) or experimentally infected chimpanzees (Bukh et al., 1998).
About 25–40% of HIV infected patients are coinfected with HPgV
(Lefrere et al., 1999; Rey et al., 2000; Xiang et al., 2001). Persistent
coinfection with HPgV in HIV infected patients is associated with
higher survival rates, lower HIV viral loads, higher CD4þ T cell
counts (Tillmann et al., 2001), decreased T cell activation (Rydze
et al., 2012; Stapleton et al., 2012) and reduction in maternal to
child HIV transmission (Handelsman et al., 2007; Supapol et al.,
2008) in most though not all studies.
HPgV is structurally and genetically similar to Hepatitis C virus
(HCV) and GB Virus-B (GBV-B). All have positive-polarity single-
stranded (9400–9600 bp) RNA genomes. HPgV and HCV have
approximately 30% amino acid sequence identity over the open
reading frame (Tanaka et al., 1996). The HCV genome is translated as
a single polyprotein, followed by co- and post-translational cleavage
by cellular and viral proteases to form 10mature proteins (Fig. 1A). The
proteins produced by HPgV have not been fully characterized, but at
least 8 mature proteins are predicted to be produced (Fig. 1A).
Nonstructural protein 3 (NS3) encodes a serine protease/heli-
case-ATPase that cotranslationally cleaves the NS3/4A, NS4A/4B,
NS4B/5A, and NS5A/5B boundaries in HCV and GBV-B (Fig. 1B)
(Raney et al., 2010; Lee et al., 2001). The conservation between
HPgV and HCV NS34A is 36%, and the protease catalytic triad is
conserved between the two viruses. HPgV NS3 has been shown to
cleave the NS3/4A, NS4B/5A, and NS5A/5B boundaries (Belyaev et
al., 1998; George et al., 2012; Lee et al., 2001). The only experi-
mentally identiﬁed nonstructural cleavage sites of HPgV are the
NS2/3 and NS4B/5A boundaries (Belyaev et al., 1998). The NS5A/5B
cleavage site has been predicted by deriving a consensus sequence
from NS3/4A-mediated peptide cleavage in vitro.
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/yviro
Virology
http://dx.doi.org/10.1016/j.virol.2014.03.018
0042-6822/Published by Elsevier Inc.
n Corresponding author at: Dept. of Internal Medicine, 8th ﬂoor Doisy Research
Bldg, Saint Louis University, 1100 S. Grand Ave, St Louis, MO 63104, USA.
Tel.: þ1 314 977 9055.
E-mail addresses: chowdhay@slu.edu (A.Y. Chowdhury),
tavisje@slu.edu (J.E. Tavis), georgesl@slu.edu (S.L. George).
Virology 456-457 (2014) 300–309
NS3 must be coexpressed with NS4A for maximal protease
activity (Belyaev et al., 1998; Failla et al., 1994). The minimal
necessary HPgV NS4A sequence required for NS3 protease activity
has been partially determined by deletion mapping (Belyaev et al.,
1998). In HCV NS3, the protease catalytic triad consists of histidine
57, aspartic acid 81 and serine 139, and independent mutation of
H57 and S139 to alanine abolishes cleavage activity (Fig. 1A)
(Bartenschlager et al., 1993; Grakoui et al., 1993; Hijikata et al.,
1993). HPgV NS3 contains an analogous triad of histidine 56,
aspartic acid 79, and serine 137, and mutating serine 137 to alanine
(S137A) in HPgV NS3 also abrogates cleavage (Belyaev et al., 1998;
George et al., 2012). We have previously shown that HPgV NS3/4A
and NS3/4AB expression in CD4þ Jurkat cells inhibits HIV replica-
tion and mutating the S137 catalytic residue to alanine (S137A)
abolishes this effect (George et al., 2012).
The type I interferon response protects cells from viral infection
by modulating cellular pathways which suppress viral replication.
Intracellular double-stranded RNA (dsRNA) is an intermediate in
Fig. 1. Schematic of the HPgV and HCV open reading frames, their cleavage recognition sequences, and the effect of mutating the HPgV protease catalytic triad on cleavage.
(A) Polyprotein map of HPgV and HCV with the amino acids of the NS3 protease catalytic triad indicated. The genes studied here are in white. (B) Experimentally determined
cleavage recognition sequences of HCV and HPgV NS3 (Belyaev et al., 1998; Lee et al., 2001; Raney et al., 2010). Conserved residues between HPgV and HCV are in bold.
(C) Map of NS3/4AB-HA constructs with each of the catalytic triad residues mutated to alanine. (D) Jurkat cells were transfected with plasmids expressing NS3/4AB-HA,
S137A, H56A, or D79A and lysates harvested at 24 h and analyzed by western blot probed with anti-HA antibody. The position of uncleaved NS3/4AB-HA (102 kDa) and
cleaved NS4B-HA (30 kDa) are indicated. Molecular markers are on the right.
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HPgV and HCV viral replication which is sensed by retinoic acid-
inducible gene 1 (RIG-I). RIG-I signals through mitochondrial
antiviral signaling protein (MAVS) (Kato et al., 2006), which is
attached to the mitochondrial surface (Kawai et al., 2005; Meylan
et al., 2005; Seth et al., 2005; Xu et al., 2005). MAVS signals
through cellular intermediates to induce phosphorylation and
translocation to the nucleus of interferon regulatory factor 3
(IRF3). IRF3 induces transcription of type I interferons, interferon-α
(IFN-α) and interferon-β (IFN-β) (Fitzgerald et al., 2003; Sato et al.,
2003).
HCV NS3/4A inhibits induction of the type I interferon response
by cleaving MAVS from the mitochondrial surface (Li et al., 2005b).
MAVS is cleaved at cysteine 508, and mutation of cysteine 508 to
arginine (C508R) abrogates cleavage (Li et al., 2005b). GBV-B and
the related canine hepatitis virus also cleave MAVS (Chen et al.,
2007; Parera et al., 2012).
Toll-like receptor 3 (TLR3) is another dsRNA sensor that detects
dsRNA inside endosomes after uptake by endocytosis. TLR3 signals
through TIR-domain-containing adapter-inducing interferon-β
(TRIF), which also leads to activation of IRF3 and induces the type
I interferon response. HCV NS3/4A has been reported to cleave
TRIF based on studies using an in vitro translation system (Li et al.,
2005a). However Dansako et al. showed that HCV NS3/4A does not
cleave TRIF in cell culture and that extracellular dsRNA interferon-
mediated signaling remains intact (Dansako et al., 2007).
HPgV and HCV coinfection occur in approximately 30–40% of
HIV patients, and studies have shown a beneﬁcial effect of HPgV
in HIV/HCV coinfection (Berzsenyi et al., 2007, 2011). HCV
NS3-speciﬁc protease inhibitors have recently been developed
for treatment of chronic HCV infection. Telaprevir and Boceprevir,
which are covalent, reversible inhibitors of HCV NS3/4A protease
are used in concert with pegylated interferon-α (PEG-IFN) and
ribavirin (RBV) to treat chronic HCV infection. Second generation
inhibitors such as Simeprevir, which has recently been approved
for clinical use (Jacobson et al., 2013; Lawitz et al., 2013; Manns et
al., 2013), and Danoprevir, are also being developed.
We hypothesized that HPgV NS3/4A cleaves MAVS and inhibits
induction of the type I interferon response similar to HCV and
GBV-B NS3/4A. We also sought to better characterize HPgV NS3
protease cleavage kinetics and determine whether or not cleavage
activity is affected by HCV protease inhibitors. Given the simila-
rities between HCV and HPgV NS3/4A, HCV protease inhibitors
could affect HPgV NS3/4A activity and inhibit HPgV replication,
potentially modulating HPgV's beneﬁcial effects in HIV and HIV/
HCV coinfection. To study HPgV NS3/4A cleavage activity, we
expressed the complete NS3/4AB polyprotein to be certain all of
the domains required for maximal activity were present (George
et al., 2012).
Results
Effect of mutating the HPgV NS3 protease catalytic residues on
cleavage of NS4B.
We ﬁrst tested the effect of separately mutating each of the
three predicted catalytic amino acids of the HPgV NS3 protease
on cleavage of NS3/4AB-HA. Serine-137, histidine-56, or aspartic
acid-79, were separately mutated to alanine in HPgV NS3/4AB-HA,
resulting in plasmids NS3/4AB-HA(S137A), NS3/4AB-HA(H56A),
and NS3/4AB-HA(D79A) (Fig. 1C and D). Jurkat cells were trans-
fected with either NS3/4AB-HA, S137A, H56A, or D79A plasmids
and cellular lysates were collected 24 h later and immunoblotted.
Cleavage activity was visualized by the appearance of NS4B-HA to
reveal whether NS3/4A was capable of cleaving NS4B-HA away
from the NS3/4AB-HA precursor polyprotein. In cell lysates
transfected with NS3/4AB-HA, complete cleavage of NS4B-HA
(30 kDa) was seen (Fig. 1D lane 1), while in cell lysates trans-
fected with S137A or H56A only uncleaved NS3/4AB-HA
(102 kDa) was seen (Fig. 1D lanes 2 and 4). Cell lysates trans-
fected with D79A accumulated smaller amounts of both cleaved
NS4B-HA and uncleaved NS3/4AB-HA, indicating partial cleavage
(Fig. 1D lane 3).
Kinetics of HPgV NS3/4AB-HA, S137A, H56A, and D79A auto cleavage
activity.
To determine the kinetics of NS3/4AB-HA and its catalytic
mutants' cleavage activity, Jurkat cells were transfected with
plasmids expressing NS3/4AB-HA, S137A, H56A, or D79A. Lysates
were collected at 1 h, 2 h, 3 h, 6 h, 8 h, 10 h, 12 h, 18 h, and 24 h
post transfection and immunoblotted with anti-HA (Fig. 2).
Protease activity was determined by the relative detection of
uncleaved NS3/4AB-HA (102 kDa) and the cleaved product
NS4B-HA (30 kDa). In NS3/4AB-HA transfected cell lysates, both
uncleaved polyprotein and cleaved NS4B-HA were detectable at
2 h (Fig. 2A lane 2) and peaked by 6–8 h. After 12 h, the amount of
uncleaved NS3/4AB-HA diminished until 24 h, when it was almost
undetectable. Cleaved NS4B-HA levels remained constant after 6 h
(Fig. 2A). In cells transfected with S137A, expression of full length
NS3/4AB-HA became detectable by 2 h and was maximal by
6 h post-transfection (Fig. 2B). After 12 h, S137A accumulation
decreased slightly but was still easily detectable at 24 h (Fig. 2B).
Fig. 2. Cleavage kinetics of HPgV NS3/4AB-HA and protease catalytic mutants.
Jurkat cells were transfected with plasmids expressing (A) NS3/4AB-HA, (B) S137A,
(C) H56A, or (D) D79A. Cell lysates were harvested at the time points indicated and
analyzed by western blots probed with anti-HA antibody. The positions of
uncleaved NS3/4AB-HA (102 kDa) and cleaved NS4B-HA (30 kDa) are indicated.
In (A) an extra lane of S137A transfected lysate is shown at extreme right as an
expression control. Molecular markers are shown on the right.
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A similar pattern of expression was seen in lysates of cells
transfected with H56A (Fig. 2C). Cells transfected with D79A
accumulated uncleaved NS3/4AB-HA by 2 h, but NS4B-HA was
not detected until 3 h, in contrast to wild-type NS3/4AB-HA where
it was detectable at 2 h. Uncleaved and cleaved products then
accumulated in similar amounts until 24 h (Fig. 2D). Thus both
S137A and H56A mutations caused complete loss of cleavage
activity similar to the corresponding mutations in HCV NS3
(Bartenschlager et al., 1993; Grakoui et al., 1993), whereas the
D79A mutant maintained delayed and less efﬁcient cleavage.
HCV protease inhibitors did not inhibit HPgV NS3/4AB-HA
autocleavage
HPgV and HCV NS3 cleavage activity in cell culture was
measured in the presence of Telaprevir, Boceprevir, or Danoprevir
to determine if HPgV NS3 protease activity is affected by HCV
protease inhibitors. Jurkat cells were transfected with HPgV
NS3/4AB-HA or HCV NS3/4A and treated with each inhibitor at
concentrations of 100 mM, 16.6 mM, 2.7 mM, and 0 mM (Fig. 3).
Efﬁciency of HCV protease activity was measured by the appear-
ance of uncleaved NS3/4A (75 kDa) compared with cleaved NS3
(73 kDa) (Fig. 3A). HCV NS3/4A cleavage was impaired by all
three HCV-speciﬁc protease inhibitors in a dose-dependent man-
ner. Partial inhibition, as shown by expression of both NS3/4A and
NS3, was seen with the addition of Z16.6 mM of Telaprevir and
Boceprevir and with 2.7 mM of Danoprevir (Fig. 3A). Danoprevir
completely inhibited cleavage at 100 mM. Thus in this this system,
Danoprevir had 6-fold more activity than Telaprevir and Boce-
previr. HPgV NS3/4AB-HA cleavage was unaffected by any of the
protease inhibitors tested at any concentration as shown by the
unvarying expression of NS4B-HA (Fig. 3B).
HPgV NS3/4AB cleaved MAVS, neither HPgV NS3/4AB nor HCV NS3/4A
cleaved TRIF
To determine if MAVS is a proteolytic target of HPgV NS3/
4AB-HA, we transfected Jurkat, Huh7, or 293T cells with expression
plasmids encoding HPgV NS3/4AB-HA, S137A, HCV NS3/4A,
HCVNS3/4A(S139A), chloramphenicol acetyl transferase (CAT), or
empty vector. Cells were lysed and MAVS was detected via western
blots (Fig. 4A–C anti-MAVS). In cells expressing S137A, S139A,
CAT or vector a 75 kDa band indicating uncleaved MAVS was
detected (Fig. 4A–C anti-MAVS lanes 2, 4, 5, and 6). In cells
expressing HPgV NS3/4AB-HA or HCV NS3/4A, a smaller
70 kDa cleaved MAVS band was seen (Fig. 4A–C anti-MAVS
lanes 1 and 3). The migration of cleaved MAVS was similar in
lysates of cells expressing HPgV NS3/4AB-HA and HCV NS3/4A,
suggesting that both proteases may cleave near the same site.
There was also a decrease in uncleaved MAVS in the HPgV NS3/
4AB-HA and HCV NS3/4A lysates of Jurkat and 293T cells com-
pared with lysates from cells expressing S137A, S139A, or controls
(Fig. 4A and C anti-MAVS lanes 1 and 3).
To determine if HPgV NS3/4AB-HA cleaves TRIF, the same cell
lysates were immunoblotted for TRIF (Fig. 4A–C anti-TRIF). There
was no change in migration of TRIF in lysates of cells expressing
HPgV NS3/4AB-HA, HCV NS3/4A, S137A, or S139A, indicating that
in transfected Jurkat, Huh7 or 293T cells neither HPgV nor HCV
NS3 detectably cleaved TRIF (Fig. 4A–C).
To conﬁrm auto cleavage of HPgV NS3/4AB-HA (30 kDa) and
HCV NS3/4A (73 kDa), the same cell lysates were immuno-
blotted with anti-HA and anti-HCV NS3 (Fig. 4A–C anti-HA lane
1 and anti-HCV NS3 lane 3). Uncleaved S137A (102 kDa) and
S139A (75 kDa) expression was also veriﬁed (Fig. 4A–C anti-HA
lane 2 and anti-HCV NS3 lane 4).
Given the conﬂicting published data on whether or not HCV
NS3 cleaves TRIF (Dansako et al., 2007; Li et al., 2005a), we
conﬁrmed the speciﬁcity of the TRIF antibody to ensure proper
identiﬁcation of TRIF in these assays. Jurkat cells were transfected
with TRIF-HA, HA-MAVS, or vector and HA-tagged proteins were
immunoprecipitated using anti-HA-conjugated agarose beads.
Lysates and immunoprecipitates were resolved using SDS PAGE
and the immunoblots were probed with anti-TRIF (Fig. 4D) or anti-
HA (Fig. 4E). Endogenous TRIF was detected in all lysates before
immunoprecipitation (Fig. 4D and E lanes 2, 4, and 6) but only in
the TRIF-HA immunoprecipitate (Fig. 4D and E lane 1), and not in
the HA-MAVS or vector-transfected immunoprecipitates (Fig. 4D
and E lanes 3 and 5). Probing with anti-HA conﬁrmed the speciﬁ-
city of the immunoprecipitation as only HA-tagged proteins were
immunoprecipitated (Fig. 4E).
Fig. 3. HCV NS3-speciﬁc protease inhibitors do not inhibit HPgV NS3/4AB-HA cleavage. Jurkat cells were transfected with plasmids expressing (A) HCV NS3/4A or (B) HPgV
NS3/4AB-HA. Telaprevir, Boceprevir, and Danoprevir were added at concentrations of 100 mM, 16.6 mM, 2.7 mM, or 0 mM in 0.1% DMSO. Lysates were harvested after 24 h and
resolved by immunoblots probed with anti-HCV NS3 (A) or anti-HA (B). The position of HCV NS3/4A (75kDa), HCV NS3 (73kDa), NS3/4AB-HA, and
NS4B-HA (30kDa) are indicated. Molecular markers are on the right.
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HPgV NS3/4AB cleaved MAVS near C508
To determine if HPgV NS3/4AB cleaves MAVS at or near the
same location as HCV NS3/4A, we cotransfected Jurkat, Huh7, and
293T cells with expression vectors encoding HPgV NS3/4AB-HA,
S137A, HCV NS3/4A, S139A, or CAT plus plasmids expressing HA-
MAVS or HA-MAVS(C508R). Cell lysates were harvested and
immunoblotted with anti-HA or anti-HCV NS3. The full length
(75 kDa) HA-MAVS band was seen in lysates of cells transfected
with HA-MAVS(C508R) plus either the active proteases or their
inactive mutants (Fig. 5A–C lanes 3, 4, 7 and 8). A smaller
(70 kDa) HA-MAVS band was detected only in lysates of cells
transfected with HA-MAVS plus HPgV NS3/4AB-HA or HCV NS3/4A
(Fig. 5A–C lanes 1 and 2), but not in lysates of cells cotransfected
with S137A or S139A (Fig. 5A–C lanes 5 and 6). These data show
that HPgV NS3/4AB-HA cleaves MAVS at or close to C508 in 3 cell
lines, similar to HCV NS3/4A (Li et al., 2005b). HPgV NS3/4AB-HA
(30 kDa) and S137A (102 kDa) expression and cleavage was
veriﬁed in the same lysates (Fig. 5 anti-HA lanes 2, 4, 6, and 8). We
conﬁrmed expression and cleavage of HCV NS3/4A (73 kDa) and
S139A (75 kDa) by immunoblotting the same lysates with anti-
HCV NS3 (Fig. 5 anti-HCV NS3 lanes 1, 3, 5, and 7).
HPgV NS3/4AB-HA cleavage activity reduced luciferase expression
from an IFN-β promoter luciferase reporter
Since HPgV NS3/4AB-HA cleaves MAVS, we tested whether
transcription from the downstream IFN-β promoter in response to
poly (I:C) stimulation was affected. We cotransfected Jurkat cells with
HCV NS3/4A, HPgV NS3/4AB-HA, S137A, S139A, CAT, or empty vector
Fig. 4. HPgV NS3/4AB cleaves MAVS but not TRIF. (A) Jurkat, (B) Huh7 and (C) 293T cells were transfected with plasmids expressing HCV NS3/4A (positive control), S139A
(negative control), HPgV NS3/4AB-HA, S137A, CAT (negative control), or empty vector (negative control). Cell lysates were harvested after 24 h and analyzed by western blot.
Blots were probed with either anti-MAVS, anti-TRIF, anti-HA or anti-HCV NS3. The positions of MAVS (75 kDa), cleaved MAVS (73 kDa), TRIF (98 kDa), HPgV NS4B-HA
(30 kDa), uncleaved NS3/4AB-HA(S137A) (102 kDa), HCV NS3/4A (73 kDa), and uncleaved NS3/4A(S139A) (75 kDa) are shown. ((D) and (E)) Jurkat cells were
transfected with plasmids expressing HA-MAVS, TRIF-HA or vector and lysates were immunoprecipitated with anti-HA. Lysates before immunoprecipitation and
immunoprecipitates were analyzed by western blot with: (D) anti-TRIF; the position of TRIF is indicated (98 kDa). (E) anti-HA; the position of HA-TRIF (98 kDa) and
HA-MAVS (75 kDa) are indicated. Molecular markers are on the right.
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plasmids plus a luciferase reporter plasmid with an IFN-β promoter
(Foy et al., 2003). The cells were transfected with HMW poly(I:C) 24 h
later and analyzed for luciferase activity after an additional 24 h.
Results were normalized to lysates of cells transfected with vector. We
conﬁrmed as found by others (Foy et al., 2003; Li et al., 2005b) that
HCV NS3/4A compared to S139A had a signiﬁcant (79% reduction,
p¼0.016) inhibitory effect on luciferase expression from the IFN-β
promoter. HPgV NS3/4AB-HA but not S137A had a similar inhibitory
effect, but it did not quite reach statistical signiﬁcance (79% reduction,
p¼0.063). These data suggest that there may be an inhibitory effect of
HPgV NS3/4AB-HA on the induction of the interferon response that is
comparable to HCV NS3/4A's effect (Fig. 6A).
HPgV NS3/4AB-HA cleavage activity reduced induction
of IFN-β transcription after poly(I:C) transfection
The reduction of luciferase activity in the IFN-β reporter assay
suggested that IFN-β production may be inhibited. Therefore we
determined if production of IFN-β mRNA transcript in cells expres-
sing HPgV NS3/4AB-HA was impaired. For this work we used 293T
cells because they have an intact RIG-I signaling pathway and high
transfection efﬁciency. We transfected 293T cells with HCV NS3/4A,
HPgV NS3/4AB-HA, S137A, S139A, CAT, or empty vector plasmids and
24 h later transfected the cells with HMW poly(I:C). As a normal-
ization control, cells transfected with empty vector were also
transfected with the diluent for poly(I:C). RNA was puriﬁed from
the transfected cells and fold change in IFN-β mRNA expression was
measured by RT-qPCR. Expression of the active protease from both
viruses signiﬁcantly lowered IFN-β mRNA expression when com-
pared to their respective inactive protease mutants (HCV NS3/4A vs.
S139A, 38% reduction, p¼0.026; HPgV NS3/4AB-HA vs. S137A, 43%
reduction, p¼0.031), demonstrating comparable inhibitory effects on
transcription (Fig. 6B). The reduction in IFN β mRNA expression
compared with vector was 28% if HCV NS3/4A was expressed
(p¼0.006) and 29% if HPgV NS3/4AB-HA was expressed (p¼0.006).
Supernatants from HPgV NS3/4AB expressing cells showed reduced
protection against VSIV-mediated CPE compared with supernatants
from S137A expressing cells
To determine if MAVS cleavage affects interferon production
from HPgV NS3/4AB-HA expressing cells enough to effect viral
growth, we measured the protective effect of type I interferon
produced in transfected cells using a CPE reduction assay. The
clariﬁed supernatants from cells in which IFN-β mRNA expression
was measured (Fig. 6B) were serially diluted and incubated with
Vero cells, which were then challenged with VSIV and quantiﬁed
for CPE. Supernatants from HCV NS3/4A and HPgV NS3/4AB-HA
expressing cells had to be signiﬁcantly more concentrated to
provide the same protection from CPE than supernatants from
cells expressing their inactive protease mutants (HCV NS3/4A vs.
S139A, 61% more concentrated, p¼0.017; HPgV NS3/4AB-HA vs.
S137A, 48% more concentrated, p¼0.0032) or vector (HCV NS3/4A
vs. vector, 55% more concentrated, p¼0.001, HPgV NS3/4AB-HA vs.
vector, 43% more concentrated, p¼0.004). The effects of both
proteases on protection from CPE caused by an IFN-sensitive virus
were comparable.
Discussion
We have previously shown that HPgV NS3/4A protease activity
inhibits HIV growth in Jurkat cells (George et al., 2012). Therefore
we wanted to better characterize its cleavage activity and kinetics
and identify cellular targets cleaved by HPgV. We also sought to
determine if HCV NS3 protease inhibitors affect HPgV NS3 activity
and whether HPgV NS3 affected the type I interferon system
strongly enough to affect viral growth. We found that HPgV NS3
cleavage activity in Jurkat cells is not affected by the anti-HCV
NS3/4A protease inhibitors Telaprevir, Boceprevir, or Danoprevir
at concentrations up to 100 mM (Fig. 3). Thus there was a wide
difference in sensitivity to HCV protease inhibitors between HCV
and HPgV NS3 proteases. We also found that HPgV cleaves MAVS
near the C508 position (Figs. 4 and 5) similar to HCV and GBV-B
(Chen et al., 2007; Li et al., 2005b), but does not cleave TRIF in
Jurkat, Huh7 or 293T cells (Fig. 4). MAVS was cleaved by HPgV
NS3/4AB-HAwith similar efﬁciency and at a site similar to the HCV
NS3/4A cleavage site (Li et al., 2005b) in three different cell
lines. This cleavage inhibited the type I interferon response as
suggested by a reporter assay (Fig. 6A) and conﬁrmed by measur-
ing IFN-β transcript levels and the ability of supernatants from
NS3-expressing cells to suppress CPE in response to a viral
infection (Fig. 6B and C).
Fig. 5. HPgV NS3/4AB cleaves MAVS at C508 similar to HCV NS3/4A. (A) Jurkat, (B) Huh7 and (C) 293T cells were cotransfected with plasmids expressing HCV NS3/4A
(positive control), S139A (negative control), HPgV NS3/4AB, S137A, or CAT (negative control) plus either HA-MAVS or HA-MAVS(C508R). Cell lysates were analyzed by
western blot. Blots were probed with either anti-HA or anti-HCV NS3. The position of HA-MAVS (75 kDa), cleaved HA-MAVS (73 kDa), HPgV NS4B-HA (30 kDa), S137A
(102 kDa), HCV NS3/4A (73 kDa) and S139A (75 kDa) are shown. Molecular markers are on the right.
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The mutations made in the catalytic triad were expected to
disable protease activity. Similar results have been seen in HCV for
H57 and S139 (Grakoui et al., 1993). In yellow fever virus muta-
tions to alanine in the H53, D77, and S138 positions all resulted
in loss of cleavage activity (Chambers et al., 1990). However, the
retention of partial activity by HPgV NS3/4AB(D79) may be
explained by the relatively less important role of the aspartic
acid in cleavage activity compared with the histidine and serine.
The catalytic serine acts as a nucleophile while the histidine
accepts the hydrogen from the serine facilitating the attack, and
the aspartic acid hydrogen bonds with the histidine to make it
more negative (Polgar, 2005).
HPgV coinfection has been associated with reduced liver disease
in HPgV/HCV/HIV triply infected patients (Barbosa Ade et al., 2009;
Berzsenyi et al., 2007, 2009, 2011). It is possible that HCV NS3
protease inhibitors could inhibit HPgV replication diminishing its
protective effect in HPgV/HCV/HIV triply infected patients. Our data
imply HCV protease inhibitors may not impair HPgV replication in
such patients. However, we were unable to directly measure the
effect of HCV protease inhibitors on HPgV replication because no
suitable cell culture system for HPgV is available. The effect of HCV
protease inhibitors on HPgV replication could be tested by measuring
HPgV viral loads in HPgV/HCV/HIV coinfected people before and
during treatment with HCV protease inhibitors.
We found that HPgV NS3/4AB inhibited the type I interferon
response via cleaving MAVS, similar to the mechanism employed by
the HCV protease (Fig. 6) (Li et al., 2005b). Inhibition of the type I
interferon response would be expected to enhance HIV replication
(Agy et al., 1995), however studies show that HIV replication is
decreased in HPgV/HIV coinfected people (Williams et al., 2004;
Xiang et al., 2001). Inhibiting the type I interferon response may also
allow increased replication of HPgV (Lau et al., 1999). This discrepancy
may be resolved by considering that increased HPgV viral levels could
in turn enhance HIV-inhibitory effects mediated by the HPgV NS5A
(Chang et al., 2007; Rydze et al., 2012; Xiang et al., 2008, 2006, 2009)
and E2 proteins (Bhattarai et al., 2013; Jung et al., 2007; Koedel et al.,
2011; McLinden et al., 2013; Mohr et al., 2010; Timmons et al., 2013;
Xiang et al., 2012). Type I interferons also promote survival of
activated T cells (Gelman et al., 2004; Marrack et al., 1999) which
are the primary host cell for HIV (Stevenson et al., 1990), and HPgV
infection is associated with reduced expression of T cell activation
markers in HIV infected people (Stapleton et al., 2012). By inhibiting
the type I interferon response, HPgV NS3 could be reducing survival
of activated T cells, reducing the number of HIV-permissive cells. This
will need to be tested in further work.
TRIF was originally proposed to be cleaved by HCV NS3 in an
in vitro translation system (Li et al., 2005a). However, Dansako
et al. (2007) could not replicate this observation in cell culture. We
were also unable to detect cleavage of TRIF by HCV or HPgV NS3 in
three separate cell lines (Fig. 4). This implies that TRIF is not
cleaved by HCV or HPgV NS3 in cell culture.
There are some limitations to our experimental methods. We use
expression plasmids for transient transfections. These plasmids only
contain speciﬁc genes from HPgV which have been HA tagged for
detection, not the entire genome. This allows us to express speciﬁc
proteins to isolate their effects, but it does not account for possible
interactions with other HPgV proteins. In addition, the proteins are
likely to be expressed at higher levels than those found during an
infection. Also, the HPgV and HCV genes used represent only one
isolate of each species, so viral genetic variation in these genes could
affect the degree to which our results can be generalized. Finally, we
used established cell lines, which are representative of but are not the
primary cells where HPgV is thought to replicate. HPgV's known host
cells are CD4þ and CD8þ T cells and B cells and possibly monocytes
(George et al., 2006). Despite the limitations of these molecular
techniques we have conﬁrmed these observations in multiple cell
Fig. 6. HPgV NS3/4AB inhibits the type I interferon response. (A) Jurkat cells
were transfected with plasmids expressing HPgV NS3/4AB-HA, S137A, HCV
NS3/4A, HCV S139A, CAT, or empty vector. After 24 h, the cells were transfected
with 0.4 mg HMW poly(I:C). Cells were lysed 24 h post poly(I:C) transfection
and luciferase activity was measured in RLU and normalized to vector-
transfected cells. (B) 293T cells were transfected with plasmids expressing
HPgV NS3/4AB-HA, S137A, HCV NS3/4A, HCV S139A, or empty vector. After
24 h, the cells were transfected with 2.5 mg HWM poly(I:C) or poly(I:C) diluent.
Cells were lysed and RNA was puriﬁed 24 h post poly(I:C) transfection. IFN-β
and GAPDH mRNA were quantiﬁed by qRT-PCR using Taqman probes. IFN-β
mRNA cycle thresholds were ﬁrst normalized to GAPDH cycle thresholds in the
same lysate and then to mRNA from cells transfected with vector and poly(I:C)
diluent. The fold change in IFN-β mRNA expression compared with vector is
shown. (C) Supernatants were collected from cells used to measure IFN-β
mRNA expression, diluted through a 2-fold series, and incubated with Vero
cells. After 24 h cells were infected with VSIV at an MOI of 0.05. 48 h after
infection, the cells were stained with crystal violet and CPE was measured as
reduction in staining. CPE was plotted against the concentration of the super-
natant to determine the EC50.
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lines or using multiple techniques such as measuring both interferon
transcripts and CPE, suggesting that these data probably reﬂect the
situation in primary cells.
This current study shows that HPgV NS3 protease has
chymotrypsin-like serine protease activity, is not inhibited by the
HCV NS3 protease inhibitors tested, and cleaves MAVS inhibiting the
type I interferon response and enhances growth of an interferon-
sensitive virus. This suggests that HCV protease inhibitors may be used
without concern for reducing HPgV's beneﬁcial effects in HPgV/HCV/
HIV triply infected patients. Inhibition of the type I interferon response
may also play a role in reducing inﬂammation and activated T cell
survival in HIV coinfected patients.
Materials and methods
Cells
CD4þ CXCR4þ Jurkat cells were maintained in RPMI supple-
mented with 10% heat-inactivated fetal calf serum (FCS) and 1%
penicillin/streptomycin/L-glutamine (P/S/G). Huh7 and Human
Embryonic Kidney cells (HEK) 293T cells were maintained in
DMEM supplemented with 10% FCS and 1% P/S/G. Vero cells were
maintained in DMEM supplemented with 5% FCS and 1% P/S/G.
Plasmids
The HA-tagged HPgV NS3/4AB and NS3/4AB(S137A) expression
plasmids have been described previously (George et al., 2012). The
H56A and D79A mutations in HPgV NS3/4AB-HA were made using
site-directed mutagenesis. The coding regions for HCV NS3/4A (nt
3419–5473) were ampliﬁed from the HCV 1a strain H77 clone
(kind gift of Dr. Charles Rice) (Blight et al., 2003) using HiFi DNA
polymerase (Roche) and inserted into pCDNA3.1/Zeoþexpression
vector (Invitrogen). The HCV NS3 serine 139 catalytic residue was
mutated to alanine (S139A) using the QuikChange II XL site-
directed mutagenesis kit (Agilent Technologies). MAVS and TRIF
coding regions were ampliﬁed from IMAGE cDNA clones 5751684
and 5180048, respectively (Open Biosystems) by PCR and inserted
into pCDNA3.1/Zeoþexpression vector. Since the TRIF IMAGE
cDNA clone has a deleted guanine at nt 1191, site-directed
mutagenesis was used to repair the deletion. The C508R mutation
in MAVS was likewise made using site-directed mutagenesis. HA
tags were inserted at the 30 terminus of the TRIF gene and at the 50
end of the MAVS gene using PCR. The chloramphenicol acetyl-
transferase (CAT) expression plasmid and the IFN-β promoter
luciferase plasmid have been described previously (Foy et al.,
2003; George et al., 2012). All genes were expressed in pcDNA
3.1/Zeoþ unless otherwise stated.
Cell transfections and western blots
2107 Jurkat cells were electroporated in duplicate with 6 mg
of HPgV, HCV or control plasmids using electroporation buffer
(7.1 mM ATP-disodium salt, 11.6 mM MgCl2–H2O, 86.5 mM
KH2PO4, 14.0 mM NaHCO3, 2.18 mM glucose) (Dr. Joseph Baldas-
sare, personal communication) in an Amaxa II nucleofector device
(program X-005) (Lonza Group). 1106 Huh7 cells were trans-
fected with 1.25 mg of expression plasmids using 3.75 ml TransIT-
LT1 Transfection Reagent (Mirus) according to the manufacturer's
instructions. 1106 293T cells were transfected with 4 mg of
expression plasmids using 10 ml Lipofectamine 2000 (Invitrogen).
After 24 h (unless otherwise speciﬁed) cells were lysed in RIPA
buffer (50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deox-
ycholate, 1% Triton-X) supplemented with protease inhibitor cock-
tail (25 ml per 1 ml) (Sigma #P8340). The protein concentration of
cell lysates was determined by BCA assay (Thermo Fisher Scien-
tiﬁc). Cell lysates (30 mg of protein) were resolved on 4–20% SDS-
PAGE gels (Lonza Group) except where speciﬁed. Cell lysates
separated by reducing SDS-PAGE were transferred to PVDF mem-
branes (Millipore) and immunoblotted using anti-MAVS (Cell
Signaling #3993), anti-TRIF (Cell Signaling #4596), anti-HCV NS3
(Thermo #MA1-7345), and anti-HA clone 3F10 (Roche #1867431)
antibodies. Western blots were visualized using BCIP/NBT color
development substrate (Promega) with an alkaline phosphatase
(AP) conjugated secondary antibody (Promega anti-Rat, anti-
Rabbit, anti-mouse).
Immunoprecipitation (IP)
2107 Jurkat cells were transfected in duplicate with 6 mg of
expression plasmid using electroporation buffer. Cell lysis was
carried out as described for western blots. Lysates were incubated
at 4 1C overnight with 50 ml of anti-HA 3F10 conjugated agarose
beads (Roche). The beads were then washed three times with
1RIPA buffer. Protein bound to agarose beads was eluted using
non-reducing 5 Laemmli buffer and boiled for 5 min to minimize
light chain contamination. Immunoprecipitates were resolved on
reducing SDS-PAGE and western blotted as described above.
Protease inhibitor evaluation
Jurkat cells were transfected with 6 mg of expression plasmids
using electroporation. HCV protease inhibitors Telaprevir, Boce-
previr, or Danoprevir (ChemScene #CS-0285, #CS-0361, #CS-0337)
were diluted in DMSO such that the ﬁnal concentration of
inhibitor was 100 mM, 16.6 mM, 2.7 mM, or 0 mM in 3 ml of media
(0.1% ﬁnal DMSO concentration). Protease inhibitors were added to
cell culture 1 h after transfection. 24 h after transfection, cells were
lysed and immunoblotted as described above.
IFN-β luciferase reporter assay in Jurkat cells
5106 Jurkat cells were electroporated in duplicate with 6 mg
of expression plasmid and 6 mg of luciferase reporter plasmid using
electroporation buffer with an Amaxa II nucleofector (program
X-001). After 24 h, cells were electroporated (program X-001)
with 0.4 mg high molecular weight (HMW) poly(I:C) (Invivogen
#tlrl-pic). 1.5105 viable transfected cells were collected and
lysed 24 h after the second transfection. Luciferase activity was
measured using the Luciferase Assay System (Promega) on a
GloMax 96 Microplate Luminometer (Promega). Relative light
units (RLU) were normalized to RLU values obtained from
vector-transfected cells.
IFN-β induction assay in 293T cells
1106 293T cells were transfected with expression plasmids as
described above. 24 h later, the cells were transfected with 2.5 mg
[1 mg/ml] of HMW poly(I:C) or poly(I:C) diluent (0.9% NaCl). After
24 h, the cells were pelleted by centrifugation at 300 g for
10 min. Supernatants were collected for cytopathic effect (CPE)
assay and cells were collected for RNA extraction. RNA was
extracted from cells using the RNeasy mini kit with QIAshredder
columns (Qiagen) for reverse transcriptase-quantitative polymer-
ase chain reaction (RT-qPCR).
RT-qPCR
5 mg of RNA was reverse transcribed (RT) using an avian reverse
transcriptase kit (Sigma #A4464) and random primers (Promega).
Quantitative PCR (q-PCR) of 200 ng cDNAwas performed using the
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Taqman assay and probes: Interferon-β assay ID Hs01077958_s1
and GAPDH assay ID Hs99999905_m1 (Life Technologies). Q-PCR
and data analysis were performed on a 7500 Real-Time PCR
System (Applied Biosystems) using software version 2.0.6. IFN-β
mRNA cycle thresholds were ﬁrst normalized to GAPDH cycle
thresholds in the same lysate then to mRNA from cells transfected
with vector and poly(I:C) diluent to measure fold change using the
ΔΔCt method.
Cytopathic effect (CPE) inhibition assay
Vero cells were plated at 1.4104 cells in 100 ml DMEM (2% FCS
and 1% P/S/G) in a 96 well plate. After 24 h, 2-fold serial dilutions
of clariﬁed supernatants collected from 293T cells transfected with
NS3/4A expression plasmids and HMW poly(I:C) as described
above were added to the cells. After 24 h, the cells were infected
with VSIV (vesicular stomatitis Indiana virus) at an MOI of 0.05.
Each plate had mock-infected (cells and media) and background
(cells and virus) wells as controls. After a 48 h incubation, cells
were incubated in methanol (100 ml per well) for 10 min, stained
with 0.05% crystal violet for 30 min, and then rinsed with water.
Crystal violet stain was solubilized by adding 100 mL methanol and
the plate was immediately read at an optical density (OD) of
595 nm using a Sunrise plate reader (Tecan) and Magellan soft-
ware 7.1. Background OD was subtracted and the corrected OD was
divided by the OD from the mock-infected wells to determine
percent CPE. The percent CPE for each dilution of supernatant was
used to plot an effective concentration at 50% (EC50) sigmoid curve
using GraphPad Prism 5.0. The EC50 values were used to compare
protective effectiveness of different supernatants against VSIV-
induced CPE.
Statistics
All applied statistics were paired t-tests with pr0.05 indicat-
ing signiﬁcance. Statistical calculations were carried out with
GraphPad Prism 5.0.
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